These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
679 related items for PubMed ID: 22362118
1. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K, AML CG study group. Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118 [Abstract] [Full Text] [Related]
4. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group. N Engl J Med; 2008 May 01; 358(18):1909-18. PubMed ID: 18450602 [Abstract] [Full Text] [Related]
5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T. Clin Cancer Res; 2005 Feb 15; 11(4):1416-24. PubMed ID: 15746041 [Abstract] [Full Text] [Related]
8. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K. Ann Hematol; 2012 Jan 15; 91(1):9-18. PubMed ID: 21744003 [Abstract] [Full Text] [Related]
9. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. Ann Hematol; 2016 Mar 15; 95(4):625-35. PubMed ID: 26692090 [Abstract] [Full Text] [Related]
13. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Ann Hematol; 2014 Aug 15; 93(8):1279-86. PubMed ID: 24801015 [Abstract] [Full Text] [Related]
14. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H. Leuk Res; 2011 Apr 15; 35(4):492-8. PubMed ID: 20684989 [Abstract] [Full Text] [Related]
20. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia]. Ruan M, Zhang L, Han C, Liu X, Ai X, Zhang J, Liu T, Yang W, Chen X, Guo Y, Wang S, Li Q, Zou Y, Chen Y, Zhu X. Zhonghua Er Ke Za Zhi; 2014 Apr 15; 52(4):303-7. PubMed ID: 24915920 [Abstract] [Full Text] [Related] Page: [Next] [New Search]